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ESSAY ON MECHANICS OF DRUG TESTING
CARLTON E. TURNER*
COLLECTION
The proper collection of the urine sample is essential for a
reliable drug test. The person to be tested must provide identifi-
cation, wash his hands prior to voiding, and deliver a required
volume of urine within an agreed-upon temperature range. A chain-
of-custody form must be initiated for each sample, and all indivi-
duals who touch the sample during the course of testing must
sign this form. The person who voided the urine then releases the
sample to the person responsible for collection. In the presence of
the person who provided the urine sample, the collector signs the
chain-of-custody form as he receives the sample and places a chain-
of-custody tape over the top of the sealed and properly labeled
bottle. The person who provided the sample then initials the label
on the container and verifies that the sample with the identification
number is actually the sample that he delivered. Using the chain-
of-custody form, the collector then releases the sample bottle to a
courier for transportation to the laboratory.
LABORATORY RECEIVING - ACCESSIONING
Upon receiving the sample, laboratory personnel sign the chain-
of-custody form, thereby stating that they received the sample.
Next, a laboratory technician inspects the sample bottle and notes
any damage (such as leakage or unusual color) on the chain-of-
custody form. The technician then assigns the sample an acces-
sioning, or processing, number. A specific gravity and pH check
may be performed at this time to insure the integrity of the
sample. An aliquot1 is then taken from the original bottle for
screening.
* President and Chief Executive Officer of Princeton Diagnostic Laboratories of America
(PDLA). Research Professor and Director of the Research Institute of Pharmaceutical
Sciences School of Pharmacy, University of Mississippi; Adjunct Research Professor, School
of Pharmacy, University of Mississippi; Senior Staff, Reagan White House, Director of Drug
Abuse Policy Office, 1981-86. Ph.D. in Organic Chemistry, University of Southern Mississippi,
1970; Post Doctoral, University of Mississippi, 1970-71; Honorary Doctorate of Science,
Albany College of Pharmacy, Union University, 1985.
1. A portion of the specimen used for testing. 49 C.F.R. S 40.3 (1990).
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SCREENING AND METHODS FOR SCREENING
The laboratory screening process varies according to the tech-
niques used. These techniques for the detection and measurement
of illegal and legal drugs of abuse in biological fluids can be
divided into two categories: the immunologic method and the
chromatographic method.
Immunologic techniques are relatively new tools. In contrast,
thin-layer chromatography (TLC) has been in use for many years
as a screening technique, but is not advisable for use in drug
screening. Each methodology is unique; no single technique is all-
encompassing. A good laboratory will offer and be proficient in a
wide variety of testing procedures and will effectively match
technology with needs.
In the discussion of drug testing methodologies, there is confu-
sion about the terms "sensitivity" and "specificity." These words
can have different meanings depending upon the person who
employs them. The technical meaning of sensitivity in drug abuse
testing is "how small a quantity can you detect?" The answer is
usually in terms of weight (or mass) per unit volume. If one asks
how sensitive a particular method is for detecting marijuana, the
answer can be down to one or less than one nanogram (ng), or
billionth of a gram, per milliliter (ng/ml). The term sensitivity is
sometimes interchangeable with the term "detection limit." Sen-
sitivity or detection limits vary with both the drug that is being
analyzed and the analytical methodology that is being used to
identify that drug.
Specificity is related to the ability of a test to exclude cross-
reactivity-other drugs reacting to the test and causing inaccurate
or false positive results. As the specificity of an analytical method
increases, the likelihood of a false positive decreases. A combina-
tion of the proper sensitivity and specificity will provide the
requisite accuracy for drug testing.
SCREENING WITH THIN-LAYER CHROMATOGRAPHY
TLC has been used traditionally as a standard "drug screen"
for drugs of abuse in a number of clinical settings. It is a relatively
fast and inexpensive test and does not require sophisticated in-
strumentation. TLC is, however, associated with an inordinate
frequency of false negatives (low sensitivity) and false positives
(low specificity). A major technical limitation of TLC is that the
results are qualitative; that is, results are reported as either
"positive" or "negative." Typically, the minimum amount of drug
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or metabolite that is necessary to yield a "positive" result falls in
the 1000 to 2000 nglml range. Thus, a negative TLC result may
mean simply that the level of sensitivity of the method is insuf-
ficient to detect the drug in that sample.
In addition, TLC suffers from low specificity. The test relies on
a reproducible migration pattern by the drug on a thin layer of
absorbent on a glass or special paper support plate. The character
and identity of an unknown drug or substance is determined by
a color reaction that is produced by spraying color-changing re-
agents on the plate containing the unknown drug. If a drug is
present in the sample, it will be identified by the distance it
migrated from the bottom of the plate toward the top of the plate,
as well as by the color produced in the migration. The laboratory
technician subjectively detects the drug by "seeing" the substance
in question with the naked eye.
SCREENING WITH IMMUNOLOGIC ASSAYS
Federal guidelines require an immunological screen. 2 The various
immunologic assays, or immunoassays, operate on the principle of
"antigen-antibody" interactions in biological fluids. Radioimmu-
noassays (RIAs), enzyme immunoassays (EIAs), and fluorescence
polarization immunoassays (FPIAs) are examples of immunologic
techniques and are relatively new tools used to detect drugs in
biological fluids. The RIA is produced by Roche, the EIA is
produced by Syva, and the FPIA is produced by Abbott. All three
systems can detect the five drugs required by federal guidelines:
marijuana, cocaine, opiates, amphetamines, and phencyclidine (PCP).3
Table I illustrates the screening methods and cut-off levels. 4
The RIA involves a gamma counter measuring the radioactivity
produced by mixing urine, blood, or another biological fluid with
2. 49 C.F.R. S 40.29 (1990) (Federal Department of Transportation); Mandatory Guidelines
for Federal Workplace Drug Testing Programs, 53 Fed. Reg. 11,970, 11,983 (1988) (estab-
lishing Department of Health and Human Services' scientific and technical guidelines for
federal drug-testing programs other than those of the military and the criminal justice
system).
3. 49 C.F.R. S 40.21; 53 Fed. Reg. 11,983.
4. A cut off level is the level at which the sample will be reported as positive for a
substance. A value below the cut off level will be reported as negative. A given drug may
have more than one cut off level; one level may reflect the industry consensus on what
value indicates the presence of the drug, and another level may conform to the needs of a
more specific purpose. See 49 C.F.R. S 40.29 for the initial cut off levels used by the
Department of Transportation and 53 Fed. Reg. 11,983 for the initial cut off levels adopted
by the Federal Department of Health and Human Services.
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a radioactive substance. EIAs test urine directly by measuring
light absorbance. The FPIA is a fluorescence technology that uses
polarization units to measure drug concentration in biological
fluids. Although many laboratories perform the EIA techniques,
the type of instrumentation that is employed produces quantitative
differences in accuracy. Sophisticated, automated instruments gen-
erally produce more accurate and reproducible results.
RIA is the oldest of the immunoassay techniques. In this pro-
cedure, the laboratory technician labels the antigen with a radio-
active substance. When a urine or blood sample is combined with
radioactive labeled drug (antigen) antibodies, the labeled drug and
the nonlabeled drug (if present in the urine or blood sample)
compete for binding sites on the antibodies. Drug presence is
indicated by measuring the unbound radioactive antigen (the drug).
The greater the amount of unbound labeled drug that is present,
the greater the amount of drug in the sample.
An EIA contains antibodies that attach themselves to drugs or
drug metabolites in a person's urine sample. The antibodies that
have not attached to a drug in the sample seek out and attach
themselves to a chemically tagged drug, which also is contained
in the EIA test. Any leftover tagged drug produces a chemical
reaction that changes the light-absorbing properties of the test
mixture. The EIA test instruments measure the sample's light
absorbency response, which is related to the amount of drug it
contains. The more drug that is present in the person's urine, the
greater the response that is produced.
FPIA is the most recent immunoassay technique adapted for
the detection of drug use. FPIA involves a competitive binding
reaction produced by the interaction of three components: the
antibody (from the reagent system), the illegal drug (within the
urine or blood sample), and the "tracer" or labeled drug (from the
reagent system). The label used to tag the drug is fluorescein. A
known amount of fluorescein labeled drug competes with the free
drug in the sample for antibody binding sites. When bound to the
antibody, the labeled drug rotates more slowly. Conversely, when
the drug is free in the solution, it rotates more rapidly. The rate
of rotation is determined through light intensity and is calculated
into polarization units by the instrument's optics and software
system. High levels of polarization correspond to low levels of the
drug, and low levels of polarization correspond to high levels of
the drug in the sample. The instrument measures polarization
values and calculates the concentration from previously stored
data.
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CONFIRMATION
All chromatographic techniques can be viewed as analytical
methods for the separation of complex mixtures of drugs into
their individual components. Gas-liquid chromatography (GLC) and
gas chromatography/mass spectrometry (GC/MS) are chromato-
graphic techniques that are used for such confirmation. Courts
have accepted GC/MS confirmation as conclusive evidence of sub-
stance use.5 Laboratory personnel can use GLC to confirm the
presence of alcohol,6 but the technique will not withstand rigid
court requirements necessary for confirming the presence of drugs.
GLC is a versatile technique that is esteemed for its sensitivity,
specificity, and speed of analysis. All GLC methods consist of the
following basic components: a carrier gas supply, a sample intro-
duction inlet, a column in a temperature-controlled oven, a detec-
tor, a recorder, and the electronics necessary for control. In
operation, the inlet vaporizes the sample and the carrier gas then
propels the sample through the column where the mixture is
separated into its components. The components pass through the
detector where they are identified; the detector response is pro-
portional to the amount of substance present in the sample.
GC/MS combines the separation versatility of a GLC detector
with the specificity of the mass spectrometer and achieves a high
specificity level. A mass spectrometer bombards the sample with
high-energy electrons to generate extensive fragmentation ions.
These ions are then plotted according to mass/charge ratio versus
intensity to create a unique fragmentation pattern. Conceptually,
this instrument may be considered to produce "fingerprints" of
chemicals. GC/MS is the most powerful technique available; its
accuracy is undisputed, and courts accept it as conclusive evidence
of substance use.7
TESTING PROTOCOL
A technically sensible and cost effective approach requires the
availability and utilization of both immunologic techniques and
5. See Skinner v. Railway Labor Executives' Ass'n, 489 U.S. 602, 610 n.3 (1989) (stating
that GCJMS can be a highly accurate test for the presence of drugs in biological samples).
6. See, e.g., id. (stating that gas chromatography can be a highly accurate test for the
presence of alcohol in biological samples); Florida v. Bender, 382 So. 2d 697, 700 (Fla. 1980)
(listing GLC as a method for determining alcohol intoxication and allowing executive agencies
to approve breath- and blood-alcohol testing methods).
7. See Skinner, 489 U.S. 602.
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chromatographic methodologies. A routine analysis can be auto-
mated and performed via an immunologic method. As the sample
is processed for screening, the original sample bottle never leaves
the secure and limited access room in which accessioning occurred.
Aliquots are taken from the original sample. If an aliquot tests
positive on the initial screen, it may be rescreened before being
sent to confirmation. Positive immunologic results must be con-
firmed by GC/IMS. Such an approach ensures the avoidance of
false positives and yet is cost effective.
REPORTING
The results of the test must be reported confidentially to protect
the individual and the employer. Verbal reporting is never allowed
because of a possible error. Courier service, facsimiles, and the
United States Postal Service may be used if such a medium is
secure and if the test results are adequately controlled at the
laboratory and receiving sites.
[Vol. 33:147
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TABLE I
Routine Routine
DRUG Screening Screening Confirmation ConfirmationMethods Cut-Off Methods (ngjml)*
Cocaine A-R-S 3001; 1503 GCIMS 1501; 503
Marijuana A-R-S 1001; 203; 503 GC/MS 151; 203; 103
Opiates A-R-S 3001 GC/MS 3001; 1003
Phencyclidine (PQP) A-R-S 25' GC/MS 251; 103
Amphetamines A-R-S 10001; 300 GC/MS 5001; 100
Methadone2  A-R-S 3003 GC/MS 300, 100 s
Barbituates2  R-S 3003 GCIMS 1003
BenzodiazepinesP S 3003 GC/MS 1003
MethaqualoneP R-S 3003 GC/MS 503
PropoxypheneP S 3003 GC/MS 100
Tricyclic 3003 HPLC 2003
AntidepressantS
Alcohol 3  A-S M 40 (mg dl)** GLC 10Pm /dl}*
Methods Key Notes Key
A = Abbott (FPIA) ' Federal guidelines
R = Roche (RIA) 2 No federal guidelines for these drugs
S = Syva (EMIT) 3 Commonly used industry standards or
HPLC = High pressure diagnostic standards
liquid * unless noted, measurements are in
chromatography billionths of a gram (nanograms)
per milliliter: ng/ml
• milligrams per deciliter: mg/dl (dl
= 100 milliliters)
